ArticleJournal of cancer research and clinical oncology2004

Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

Lorella Bonaccorsi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.